Allergic Asthma
Conditions
Keywords
Airway hyperresponsiveness
Brief summary
BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.
Interventions
DRUGSalmeterol and Salmeterol / Fluticasone
Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
Sponsors
GlaxoSmithKline
University of Rostock
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years, a physician's diagnosis of allergic asthma * A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite) * A pre-bronchodilator forced expiratory volume in the first second (FEV1) \> 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of \< 8 mg histamine / ml
Exclusion criteria
* No regular treatment (only short-acting inhalers on demand were allowed) * No history of or evidence for any other chronic disease than asthma * No history of smoking, absence of any signs or symptoms of an infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BDNF concentrations in serum, platelets and plasma | 2006 - 2007 |
Secondary
| Measure | Time frame |
|---|---|
| Airway hyperresponsiveness | 2006 - 2007 |
Countries
Germany
Outcome results
None listed